OSE Pharma is a privately held clinical stage biopharmaceutical company with its corporate headquarters in Paris, France. OSE Pharma is developping a Cancer Specific Immunotherapy in Phase 3 for Lung cancer (NSCLC) and Phase 2 status in other cancers. OSE Pharma acquired its Multi-Epitope T-Cytotoxic technology from a Multinational pharmaceutical company.
The Company is targeting cancer and pulmonary diseases and seeks to transform lives through the discovery, development, and manufacture of novel therapeutics that significantly improve treatment options for patients. OSE Pharma is managed by Dominique Costantini, M.D, and Emile Loria, M.D. Both are experienced professionals, with complementary expertise in successfully managing drug development and business operations in public companies in the US (Epimmune - Nasdaq) and in Europe (BioAlliance - Euronext).